Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma

Anti-programed cell death-1 (Anti-PD-1) is a promising immunotherapy for advanced cancers. Autoimmune pneumonitis is a rare but potentially serious toxicity induced by anti-PD-1 immunotherapy. We report a case of therapy-induced pneumonitis in the setting of combined nivolumab, anti-PD-1 immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Nathan Y, Deftos, Michael, Wang, Clifford C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388854/
https://www.ncbi.nlm.nih.gov/pubmed/30820369
http://dx.doi.org/10.7759/cureus.3748
_version_ 1783397834188390400
author Yu, Nathan Y
Deftos, Michael
Wang, Clifford C
author_facet Yu, Nathan Y
Deftos, Michael
Wang, Clifford C
author_sort Yu, Nathan Y
collection PubMed
description Anti-programed cell death-1 (Anti-PD-1) is a promising immunotherapy for advanced cancers. Autoimmune pneumonitis is a rare but potentially serious toxicity induced by anti-PD-1 immunotherapy. We report a case of therapy-induced pneumonitis in the setting of combined nivolumab, anti-PD-1 immunotherapy, and radiation therapy for metastatic renal cell carcinoma (RCC).
format Online
Article
Text
id pubmed-6388854
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-63888542019-02-28 Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma Yu, Nathan Y Deftos, Michael Wang, Clifford C Cureus Pathology Anti-programed cell death-1 (Anti-PD-1) is a promising immunotherapy for advanced cancers. Autoimmune pneumonitis is a rare but potentially serious toxicity induced by anti-PD-1 immunotherapy. We report a case of therapy-induced pneumonitis in the setting of combined nivolumab, anti-PD-1 immunotherapy, and radiation therapy for metastatic renal cell carcinoma (RCC). Cureus 2018-12-18 /pmc/articles/PMC6388854/ /pubmed/30820369 http://dx.doi.org/10.7759/cureus.3748 Text en Copyright © 2018, Yu et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pathology
Yu, Nathan Y
Deftos, Michael
Wang, Clifford C
Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma
title Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma
title_full Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma
title_fullStr Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma
title_full_unstemmed Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma
title_short Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma
title_sort pneumonitis in combined anti-programmed death-1 immunotherapy and radiation therapy for renal cell carcinoma
topic Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388854/
https://www.ncbi.nlm.nih.gov/pubmed/30820369
http://dx.doi.org/10.7759/cureus.3748
work_keys_str_mv AT yunathany pneumonitisincombinedantiprogrammeddeath1immunotherapyandradiationtherapyforrenalcellcarcinoma
AT deftosmichael pneumonitisincombinedantiprogrammeddeath1immunotherapyandradiationtherapyforrenalcellcarcinoma
AT wangcliffordc pneumonitisincombinedantiprogrammeddeath1immunotherapyandradiationtherapyforrenalcellcarcinoma

Ejemplares similares